It is derived from 2 subjective parameters, that is, tender joints (TJ) count and patient global assessment and 2 objective parameters, that is, swollen joints (SJ) count and laboratory value of CRP.[11] DAS28-CRP is a valuable tool to optimize outcome in RA patients, by means of measuring disease activity and thereafter adjusting treatment, that is, “treat-to-target.”[11]. The gene discussed is CRP; the disease is rheumatoid arthritis.